ConductScience.org, home

Trial · NCT04746989

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

NCT04746989, Completed, Brigham and Women's Hospital; results first posted 2026-02-27

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol. Trials, record NCT04746989. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04746989

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
NCT number
NCT04746989
Status
Completed
Enrollment
294,878 participants, actual
Lead sponsor
Brigham and Women's Hospital
Conditions
Gout
Interventions
Probenecid, Allopurinol
First posted
2021-02-10
Last updated
2026-02-27
Results first posted
2026-02-27

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryTime to Dementia OnsetMedian follow up times: 1) 36 days (exp), 214 days (ref) 2) 1095 days (exp), 1095 days (ref) 3) 565 days (exp), 372 days (ref) 4) 36 days (exp), 248 days (ref)
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYTime to Dementia OnsetMedian follow up times: 1) 36 days (exp), 214 days (ref) 2) 1095 days (exp), 1095 days (ref) 3) 565 days (exp), 372 days (ref) 4) 36 days (exp), 248 days (ref)Study cohort after 1:1 propensity score matchingIncidence rate per 1000 person yearNUMBER

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Time to Dementia OnsetProbenecidAnalysis 114.4495% Confidence Interval 11.46 to 17.94Incidence rate per 1000 person year
Time to Dementia OnsetAllopurinolAnalysis 118.2395% Confidence Interval 16.00 to 20.69Incidence rate per 1000 person year
Time to Dementia OnsetProbenecidAnalysis 222.0795% Confidence Interval 18.71 to 25.85Incidence rate per 1000 person year
Time to Dementia OnsetAllopurinolAnalysis 219.4095% Confidence Interval 16.25 to 23.00Incidence rate per 1000 person year
Time to Dementia OnsetProbenecidAnalysis 315.8795% Confidence Interval 12.56 to 19.78Incidence rate per 1000 person year
Time to Dementia OnsetAllopurinolAnalysis 317.5495% Confidence Interval 13.62 to 22.24Incidence rate per 1000 person year
Time to Dementia OnsetProbenecidAnalysis 44.9695% Confidence Interval 3.29 to 7.16Incidence rate per 1000 person year
Time to Dementia OnsetAllopurinolAnalysis 46.2995% Confidence Interval 5.02 to 7.79Incidence rate per 1000 person year

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDProbenecid8,115
Overall StudySTARTEDAllopurinol286,763
Overall StudyCOMPLETEDProbenecid8,115
Overall StudyCOMPLETEDAllopurinol8,115
Overall StudyNOT COMPLETEDProbenecid0
Overall StudyNOT COMPLETEDAllopurinol278,648

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityProbenecid08,115
Total, all-cause mortalityAllopurinol08,115
Total, other adverse eventsProbenecid08,115
Total, other adverse eventsAllopurinol08,115
Total, serious adverse eventsProbenecid00
Total, serious adverse eventsAllopurinol00

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Probenecid vs Allopurinol: deaths from any cause

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04746989

GET https://conductscience.org/api/trials/v1/NCT04746989/registered